Publications | Lund University Publications

1 – 3 of 3

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=author+exact+med-kry+or+(documenttype+any+%2522bookEditor%2520conferenceEditor%2522+and+editor+exact+med-kry)&q=department+exact+V1001088&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2022
Mark Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial
Fjordén, Karin ^LU ; Ekberg, Sara ; Kuric, Nevzeta ; Smedby, Karin E. ; Lagerlöf, Ingemar ; Larsen, Thomas S. ; Jørgensen, Judit M. ; de Nully Brown, Peter and Jerkeman, Mats ^LU (2022) In British Journal of Haematology 196(2). p.437-440
- Contribution to journal › Letter
2012
Mark Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma
Fjordén, Karin ^LU ; Joost, Patrick ^LU ; Ehinger, Mats ^LU ; Edén, Patrik ^LU ; Jerkeman, Mats ^LU ; Cavallin-Ståhl, Eva ^LU and Linderoth, Johan ^LU (2012) In Leukemia & Lymphoma 53(9). p.1764-1768
- Contribution to journal › Article
2010
Mark CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Fjordén, Karin ^LU ; Linderoth, Johan ^LU ; Nyman, Heidi ; Ehinger, Mats ^LU ; Joost, Patrick ^LU ; Bendahl, Pär-Ola ^LU ; Leppä, Sirpa and Jerkeman, Mats ^LU (2010) In Leukemia & Lymphoma 51. p.1643-1648
- Contribution to journal › Article

your query:: Remove author: Fjordén, Karin (LU); Remove department: Lymphoma - Clinical Research